Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

Both sacubitril/valsartan (Entresto) and enalapril (Vasotec) were associated with improvement in clinical measures among children aged 1 month to younger than 18 years who had heart failure ...

Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when ...